ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients

F. J. Marco Canosa1, K. Brizendine2, H. Hassouna3

1Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, 2Infectious Disease, Cleveland Clinic Foundation, Cleveland, OH, 3Infectious Disease, Spectrum Health Infectious Disease, Grand Rapids, MI

Meeting: 2019 American Transplant Congress

Abstract number: C336

Keywords: Fungal infection, Lung transplantation, Prophylaxis

Session Information

Date: Monday, June 3, 2019

Session Name: Poster Session C: Lung: All Topics

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Hall C & D

Related Abstracts
  • Itraconazole Prophylaxis, Trough Concentration, and Identification of Fungal Pathogens in Lung Transplant
  • Target Itraconazole Trough Concentration for Prophylaxis in Lung Transplant

*Purpose: Cystic fibrosis (CF) patients exhibit unique pharmacokinetic principles. Azole antifungals show marked inter- and intra-patient variability. We aimed to improve itraconazole (ITR) use and determine the association with post-transplant fungal pathogen identification in CF lung transplant recipients (LTR) compared to non-CF.

*Methods: We conducted a retrospective cohort study of adult LTR from 2012-2017.

*Results: We identified 528 LTR, 39 CF LTR on 26,341 days of ITR who underwent 80 serum trough concentration measurements and 489 non-CF LTR on 363,226 days of ITR who underwent 1,065 serum trough concentration measurements. All CF patients and 481/489 (98%) non-CF LTR initially received 200 mg per day as suspension. Proton pump inhibitors were used in 34/39 (87%) of the CF patients and 450/489 (92%) of the non-CF patients. We compared ITR levels between the 2 groups. 56% of the CF LTR had initial levels <0.5 (level obtained after a median of 22 days of ITR) compared with 32% for non-CF (p<0.01). Only 8/19 (42%) CF LTR had their dose increased. At later points, significant differences in the ITR levels remained: for CF LTR, 50% had ITR level <0.5 vs. 30% for non-CF at 2ndtime point, and 56 vs. 30% at 3rd. We next evaluated BAL fluid studies to compare fungal pathogens. 14/39 (36%) CF LTR had fungal pathogens identified a median of 88 days after transplant: 10 Aspergillus, 1 Scedosporium, and 3 other. 138/489 (28%) non-CF had fungal pathogens identified a median of 100 days after transplant: 94 Aspergillus, 5 Purpureocillium, 3 Fusarium, 3 Alternaria, 1 Scedosporium, 1 Scopulariopsis, 1Ochroconis gallopavum.

*Conclusions: CF is a significant risk factor for sub-therapeutic ITR trough concentrations post lung transplant. The risks of exposure to such low ITR levels need to be determined. One possible risk involves development of invasive fungal infection. Although in our study there were more fungal pathogens identified in BAL fluid analysis of CF LTR, the difference between CF and non-CF LTR did not reach statistical significance. Dose escalation in CF LTR with close monitoring appears needed to improve prophylaxis in this vulnerable population with unique pharmacokinetic principles at risk of invasive fungal infection.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Canosa FJMarco, Brizendine K, Hassouna H. Azole Use and Fungal Pathogens in Cystic Fibrosis versus Non-Cystic Fibrosis Lung Transplant Recipients [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/azole-use-and-fungal-pathogens-in-cystic-fibrosis-versus-non-cystic-fibrosis-lung-transplant-recipients/. Accessed December 7, 2019.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Tacrolimus Dose and Trough Blood Levels in a US Liver Transplant Population
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2019 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

wiley-new-logo

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.